Cerebral Therapeutics LLC   Report issue

For profit Phase 2
Founded: Aurora CO United States (2010)
Status: No NME R&D (2010)

Organization Overview

First Clinical Trial
2016
NCT02899611
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Cerebral Therapeutics LLC

Active Ingredients

Drugs in Phase 2 Trials (2)

ct-010 (1 trial)

valproic acid (depakene) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Drug Resistant Epilepsy (Phase 2)

Epilepsies, Partial (Phase 2)

Epilepsy (Phase 2)

Seizures (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2